Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Should upfront CAR-T be part of the early MM treatment?

Philip McCarthy • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Antibodies CAR-T Daratumumab
Bluebird

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses whether upfront CAR-T cell therapy should be part of the early MM treatment. BCMA, MRD and antibody-drug conjugates are also discussed. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Philip McCarthy

4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals